Is HELE a Buy or a Sell? The Bull and Bear Case (2026)

Last updated October 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for Helen of Troy Limited (HELE) rests on Leadership Brand portfolio: Helen of Troy concentrates investment behind a handful of scaled brands including OXO, Hydro Flask, Osprey, Vicks, Braun and Honeywell. The bear case rests on revenue growth is minimal (~2% year over year in the latest quarter) and Beauty & Wellness sales are still declining, so a sustained rebound is not guaranteed given consumer discretionary softness and competitive private-label pressure. Analysts covering it publish targets from $26.00 to $40.00 against a $28.99 price, so even the professionals disagree by 44% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

Helen of Troy Limited designs, markets and distributes consumer products across two segments: Home & Outdoor (OXO kitchen and storage tools, Hydro Flask hydration bottles, Osprey packs, PUR filtration) and Beauty & Wellness (Braun and Vicks health devices, Honeywell air treatment, Hot Tools and Drybar hair appliances, Curlsmith). The company sells through mass retail, specialty, and online channels, and manages a portfolio it calls its Leadership Brands while periodically acquiring and divesting smaller labels. Trailing revenue is roughly $1.83 billion (as of October 2026), and the business generates meaningful free cash flow (~$112 million over the trailing twelve months) even as top-line sales have been roughly flat to down. The investment picture is that of a leveraged turnaround that has started to show progress. HELE reported a large GAAP net loss for fiscal 2026 (~$899 million) driven mainly by an ~$886 million non-cash goodwill and intangibles writedown, and trailing GAAP net income is still negative (~-$99 million) as that charge works through the numbers. In its fiscal Q2 2027 (quarter ended August 31, 2026, reported October 8), net sales rose 2.1% to ~$441 million and adjusted EPS of $0.79 beat the ~$0.50 consensus, helped by an 800 basis point jump in gross margin to 52.2%, partly from tariff refunds. Total debt fell to ~$673 million from ~$893 million a year earlier, and management raised its full-year adjusted EPS and free cash flow guidance. With a market cap near $704 million against ~$1.83 billion of sales, the stock trades at a price-to-sales multiple of about 0.4 and roughly 7.8 times forward earnings. Bulls focus on cash generation, cost restructuring (the Pegasus program), deleveraging and cheap valuation; bears point to flat revenue, the Beauty & Wellness decline and the one-off nature of tariff refunds.

The bull case: what would have to be true for $40.00

The most optimistic published target on HELE is $40.00, +38.0% from the $28.99 price as of October 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

1. Leadership Brand portfolio

Helen of Troy concentrates investment behind a handful of scaled brands including OXO, Hydro Flask, Osprey, Vicks, Braun and Honeywell. Performance is uneven across the portfolio: in fiscal Q2 2027 Home & Outdoor sales rose 9.2% to ~$228 million while Beauty & Wellness sales fell 4.5% to ~$213 million (as of October 2026). The near-term story is about stabilizing the softer beauty and wellness lines while defending share in the stronger home and outdoor brands.

2. Cost restructuring and cash flow

The Pegasus and related restructuring programs aim to cut costs, simplify operations and lift margins. Adjusted operating margin rose 240 basis points to 8.6% in fiscal Q2 2027, and management raised its fiscal 2027 free cash flow outlook to $120-140 million (from $85-100 million) as of October 2026. That cash has been directed toward debt reduction rather than buybacks or a dividend.

3. Debt paydown and balance sheet

Total debt fell to roughly $673 million at the end of fiscal Q2 2027, down from ~$893 million a year earlier, and net leverage improved to about 3.0x from 3.5x the prior quarter (as of October 2026). Management targets net leverage of 2.7x or lower by fiscal year end. Continued free cash flow that reduces borrowings would lower interest expense and financial risk, while any cash-flow shortfall would leave the balance sheet stretched, with cash of only ~$23 million on hand.

4. Tariff and cost management

Much of Helen of Troy's product is sourced abroad, so tariffs and input costs directly pressure gross margin. The picture improved in fiscal Q2 2027: gross margin reached 52.2%, with tariff effects contributing about 560 basis points, and the company booked ~$26.9 million of gross pretax tariff refunds, most of which it reinvested (net benefit about $0.12 per share). Management's fiscal Q3 guidance includes an estimated $0.66-0.77 per share tariff refund benefit, so part of the near-term earnings lift is not recurring.

The bear case: what would have to be true for $26.00

The most pessimistic published target is $26.00, -10.3% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks Helen of Troy Limited is worth if the risks below bite instead of the drivers above.

Revenue growth is minimal (~2% year over year in the latest quarter) and Beauty & Wellness sales are still declining, so a sustained rebound is not guaranteed given consumer discretionary softness and competitive private-label pressure. The company carries meaningful debt (~$673 million as of October 2026) against little cash, so a downturn in cash flow would raise refinancing and covenant risk. Part of the recent margin and earnings improvement comes from tariff refunds that will not repeat, and future tariff policy could swing the other way. The large goodwill writedown signals that past acquisitions were carried above their current worth. HELE pays no dividend, and after a ~46% gain in 2026 the shares sit near their 52-week high of ~$32, close to the average analyst target, so the low multiple to sales reflects genuine uncertainty rather than a guaranteed value opportunity.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding HELE already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on HELE

3 analysts cover HELE, with an average target of $31.67 (+9.2% against $28.99) and a split of 1 buy, 3 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the HELE forecast and price target page.

How is HELE valued? (as of October 2026)

Price

$28.99

Market cap

$678.09M

Forward P/E

7.47

Price / book

0.80

Beta

1.34

52-week range

$13.85 to $31.98

Snapshot for HELE as of October 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.

Revenue (TTM): ~$1.83 billion
Q2 FY2027 net sales: ~$441 million (+2.1% YoY)
Q2 FY2027 adjusted EPS: $0.79 vs ~$0.50 estimate
Gross margin (TTM): ~45.8%
Forward P/E: ~7.8x
Market cap: ~$704 million
Total debt: ~$673 million
FY2027 guidance: Net sales ~$1.77-1.82 billion; adj. EPS $3.60-4.15

HELE trades at roughly 0.4 times sales and about 7.8 times forward earnings (as of October 2026), a low multiple that reflects flat revenue and a leveraged balance sheet even after the shares rose ~46% this year. Trailing GAAP earnings remain negative because of the ~$886 million fiscal 2026 goodwill and intangibles writedown, so forward adjusted EPS, free cash flow and the pace of debt reduction are the more useful gauges. Some of the fiscal 2027 earnings lift comes from one-time tariff refunds, which flatters the forward multiple.

How do you decide if HELE is a buy?

Rather than asking whether HELE is a buy in the abstract, it tends to help to answer four questions:

Thesis: do you believe the bull case above, and is it still true today?
Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
Overlap: check whether you already hold HELE indirectly through an index or sector ETF before adding more.

What would change your mind on HELE

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

Bull case breaks if: Leadership Brand portfolio stalls in the reported numbers rather than in the narrative around them.
Bear case breaks if: revenue growth is minimal (~2% year over year in the latest quarter) and Beauty & Wellness sales are still declining, so a sustained rebound is not guaranteed given consumer discretionary softness and competitive private-label pressure fails to materialise over several reporting periods while the drivers keep compounding.
Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the HELE stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about HELE against your real portfolio and see your actual exposure before deciding.

Investing in Helen of Troy Limited with AI

Connect the broker you already use and ask Walnut's AI how HELE fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.

Does HELE fit me?

FAQ

Is HELE a good stock to buy right now?

That depends on which case you find more convincing, and both are on this page. The bull case rests on Leadership Brand portfolio, with revenue (ttm) at ~$1.83 billion. The bear case rests on revenue growth is minimal (~2% year over year in the latest quarter) and Beauty & Wellness sales are still declining, so a sustained rebound is not guaranteed given consumer discretionary softness and competitive private-label pressure. Analysts covering it are spread from $26.00 to $40.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Should I sell HELE?

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Revenue growth is minimal (~2% year over year in the latest quarter) and Beauty & Wellness sales are still declining, so a sustained rebound is not guaranteed given consumer discretionary softness and competitive private-label pressure. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $26.00, -10.3% from the $28.99 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

What is the bull case for HELE?

Leadership Brand portfolio. Helen of Troy concentrates investment behind a handful of scaled brands including OXO, Hydro Flask, Osprey, Vicks, Braun and Honeywell. The most optimistic analyst target on HELE is $40.00, +38.0% from the $28.99 price. That figure is only reachable if this thesis works close to its best case.

What is the bear case for HELE?

What does Helen of Troy Limited do?

Helen of Troy Limited designs, markets and distributes consumer products across two segments: Home & Outdoor (OXO kitchen and storage tools, Hydro Flask hydration bottles, Osprey p

What would have to change for HELE to stop being worth holding?

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Leadership Brand portfolio) stalling in the reported numbers rather than in the narrative, the risk above (revenue growth is minimal (~2% year over year in the latest quarter) and Beauty & Wellness sales are still declining, so a sustained rebound is not guaranteed given consumer discretionary softness and competitive private-label pressure) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

What does Helen of Troy do?

It designs, markets and distributes consumer products across two segments, Home & Outdoor and Beauty & Wellness, under brands including OXO, Hydro Flask, Osprey, Vicks, Braun, Honeywell, PUR, Hot Tools and Drybar. It sells through retail, specialty and online channels.

Why is Helen of Troy stock so cheap relative to its sales?

As of October 2026 the market cap (~$704 million) is under 40% of trailing revenue (~$1.83 billion), even after a ~46% rise in 2026. The low multiple reflects flat sales, tariff exposure, meaningful debt (~$673 million) and a large recent goodwill writedown, not a settled bargain.

Did Helen of Troy report a big loss?

It reported a large GAAP net loss for fiscal 2026 (~$899 million), but the bulk came from a non-cash goodwill and intangibles writedown of roughly $886 million. Adjusted earnings and free cash flow stayed positive, and the two most recent quarters were GAAP profitable (~$36 million and ~$5 million of net income).

Walnut is informational, not investment advice, and gives no verdict on HELE. Analyst targets referenced here come from a October 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.